Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

21 Aug 2019

Abstract excerpt

Before initiating treatment of advanced non–small-cell lung cancer with tyrosine kinase inhibitors (eg, erlotinib, gefitinib, osimertinib, and afatinib), which inhibit the catalytic activity of epidermal growth factor receptor (EGFR), clinical guidelines require determining the EGFR mutational status for activating ( EGFR exons 18, 19, 20, or 21) and resistance ( EGFR exon 20) mutations. The EGFR resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31445213
DOI: 10.1016/j.jmoldx.2019.06.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung CancerPMID 31445213Read ↗

Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results.Semantic proximity Read ↗

Use of the Idylla EGFR Mutation Test for Variant Detection in Non-Small Cell Lung Cancer Samples.Semantic proximity Read ↗

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day.Semantic proximity Read ↗

Rapid EGFR evaluation from used H&E, IHC and FISH diagnostic slides with the Idylla platform.Semantic proximity Read ↗

Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples.Semantic proximity Read ↗

Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Evaluation of the Idylla system to detect the EGFRT790M mutation using extracted DNA.Semantic proximity Read ↗

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.Semantic proximity Read ↗

Feasibility of EGFR Mutation Testing Without Nucleic Acid Extraction in Scraped Cytologic Samples Using the Idylla Platform.Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

Clinical Performance Evaluation Of The Idylla™ Egfr Mutation Test On Formalin-Fixed Paraffin-Embedded Tissue Of Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.